Corcept Therapeutics (CORT) said Monday that results from its phase 3 study of relacorilant to treat patients suffering from endogenous hypercortisolism showed clinically "meaningful and durable cardiometabolic improvements."

Hypercortisolism, or Cushing's syndrome, occurs when the body produces too much cortisol, which can cause high blood pressure leading to increased cardiovascular risk and mortality.

At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure and mean diastolic blood pressure, compared with their measurement at entry into the long-term extension study, the company said.

Relacorilant was well-tolerated, with a treatment duration of up to six years, the company added. It also said it will use the data to support a new-drug application with the US Food and Drug Administration, which it expects to submit this month.

Shares of Corcept Therapeutics were up 2% in recent premarket activity.